Explore

Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal
Trendline Trendline
Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact

Revolution Medicines' Pancreatic Cancer Drug Poised for FDA Approval, Analysts Predict Major Impact
Trendline Trendline
Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients

Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients

Agenus Publishes Promising Phase 1b Data on Botensilimab and Balstilimab for Liver Cancer Patients
Trendline Trendline
Ferring Pharmaceuticals' ADSTILADRIN Shows Promise in Real-World Bladder Cancer Treatment

Ferring Pharmaceuticals' ADSTILADRIN Shows Promise in Real-World Bladder Cancer Treatment

Ferring Pharmaceuticals' ADSTILADRIN Shows Promise in Real-World Bladder Cancer Treatment
Rapid Read Rapid Read
FDA Approves Genentech's Tecentriq for Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment

FDA Approves Genentech's Tecentriq for Muscle-Invasive Bladder Cancer with ctDNA-Guided Treatment

The U.S. Food and Drug Administration (FDA) has approved Genentech's Tecentriq (atezolizumab) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) after cystectomy. This approval marks the first ctDNA MRD-guided therapy, allowing healthcare professionals to tailor treatment to improve clinical benefits and reduce unnecessary interventions. The decision was based on the Phase III IMvigor011 study, which demonstrated that Tecentriq reduced the risk of disease recurrence or death by 36% and the risk of death by 41% in patients with detectable ctDNA MRD. The study utilized Natera's Signatera CDx personalized MRD assay to identify molecular evidence of cancer in the blood, enabling selective deployment of adjuvant immunotherapy.
Rapid Read Rapid Read
RAGE Receptor Linked to Increased Breast Cancer Mortality in Older Patients

RAGE Receptor Linked to Increased Breast Cancer Mortality in Older Patients

Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified the receptor for advanced glycation end-products (RAGE) as a key factor in worsening breast cancer outcomes among older patients. The study, conducted using mouse models and human breast cancer samples, found that RAGE amplifies inflammatory signaling, which becomes more active with metastatic progression. The findings suggest that inhibiting RAGE could serve as an effective adjunctive therapy for older breast cancer patients. The research highlights the role of aging in cancer metastasis and the potential for targeting RAGE to improve treatment outcomes.
Rapid Read Rapid Read
RAGE Receptor Linked to Increased Breast Cancer Metastasis in Older Patients

RAGE Receptor Linked to Increased Breast Cancer Metastasis in Older Patients

Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified the RAGE receptor as a key factor in the increased metastasis of breast cancer in older patients. The study, conducted on mouse models and human breast cancer samples, found that aging enhances inflammatory pathways that activate RAGE, facilitating cancer spread. The findings suggest that inhibiting RAGE could serve as a potential therapeutic strategy to mitigate breast cancer progression in older individuals. The study highlights the role of systemic factors like aging and inflammation in cancer behavior, challenging the focus on genetic mutations alone.
Rapid Read Rapid Read
Revolutionary Cancer Treatment Discovery Recognized with Prestigious Award

Revolutionary Cancer Treatment Discovery Recognized with Prestigious Award

Davis Joseph has been awarded the 2025 Ciechanover International Biology Award for his groundbreaking discovery in cancer treatment. His research identifies universal cancer types based on the malfunction of specific proteins and regulatory RNAs, challenging traditional organ-specific treatment paradigms. This discovery paves the way for an organ-agnostic approach to oncology, potentially revolutionizing cancer treatment by targeting cancer types rather than the organs they affect. Joseph's work includes the development of a universal apoptosis network flowsheet, which maps the complex interactions between proteins and regulatory RNAs, offering new therapeutic targets for cancer treatment.
Rapid Read Rapid Read
Georgetown Researchers Identify RAGE as Key Factor in Breast Cancer Mortality with Age

Georgetown Researchers Identify RAGE as Key Factor in Breast Cancer Mortality with Age

Researchers at Georgetown’s Lombardi Comprehensive Cancer Center have identified the receptor for advanced glycation end-products (RAGE) as a significant factor in worsening breast cancer outcomes in older patients. The study, conducted on mouse models and human breast cancers, found that RAGE amplifies inflammatory signaling, which increases with metastatic progression. The research suggests that inhibiting RAGE could serve as an adjunctive therapy for older breast cancer patients. The study highlights the role of aging in altering the host environment, influencing immune function and chronic inflammation, which in turn affects cancer behavior.
Rapid Read Rapid Read
Georgetown Study Links RAGE to Increased Breast Cancer Metastasis in Older Patients

Georgetown Study Links RAGE to Increased Breast Cancer Metastasis in Older Patients

Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified the receptor for advanced glycation end-products (RAGE) as a key factor in the increased metastasis of breast cancer in older patients. The study, conducted on both mouse models and human breast cancer samples, found that RAGE amplifies inflammatory signaling, which becomes more active with metastatic progression. The research suggests that inhibiting RAGE could serve as a well-tolerated adjunctive therapy for older breast cancer patients. The study highlights that aging significantly increases breast cancer metastasis, with RAGE playing a crucial role in this process. The findings are published in Communications Biology and suggest that targeting RAGE could mitigate age-related cancer progression.
Rapid Read Rapid Read
CancerCheck and Evexia Partner to Enhance Early Cancer Detection Nationwide

CancerCheck and Evexia Partner to Enhance Early Cancer Detection Nationwide

Cancer Check Labs has announced a strategic partnership with Evexia Diagnostics to improve early cancer detection across the United States. The collaboration involves CancerCheck, a multi-cancer early detection test that uses a minimally invasive blood test to extract whole circulating tumor cells (CTCs). This test allows a board-certified pathologist to deliver a detailed pathology report. Unlike other tests that rely on biomarkers or DNA, CancerCheck isolates whole CTCs, providing a more accurate diagnosis. The partnership with Evexia will leverage its extensive lab network to make CancerCheck more accessible to clinicians and patients, offering the test through in-office or at-home blood collection. This initiative aims to enhance early cancer detection, potentially identifying cancer as early as Stage 0.